| Literature DB >> 29888951 |
Sarah W Curtis1, Karen N Conneely1,2, Mary E Marder3, Metrecia L Terrell4, Michele Marcus3,4,5, Alicia K Smith1,6,7.
Abstract
Endocrine-disrupting compounds (EDCs) are a broad class of chemicals present in many residential products that can disrupt hormone signaling and cause health problems in humans. Multigenerational cohorts, like the Michigan polybrominated biphenyl registry, are ideal for studying the effects of intergenerational exposure. Registry participants report hormone-related health problems, particularly in those exposed before puberty or those in the second generation exposed through placental transfer or breastfeeding. However, more research is needed to determine how EDCs cause health problems and the mechanisms underlying intergenerational exposure. Utilizing existing data in this registry, along with genetic and epigenetic approaches, could provide insight to how EDCs cause human disease and help to determine the risk to exposed populations and future generations.Entities:
Keywords: epigenetic effects; epigenetic epidemiology; environmental epigenomics
Mesh:
Substances:
Year: 2018 PMID: 29888951 PMCID: PMC6275560 DOI: 10.2217/epi-2017-0174
Source DB: PubMed Journal: Epigenomics ISSN: 1750-192X Impact factor: 4.778
Timeline of the Michigan incident.
Polybrominated biphenyl levels required for health problems in animal models.
| Death | 25,000 mg/day (262,879 ppm) | |||
| Depressed heart rate | 25,000 mg/day (262,879 ppm) | |||
| Depressed respiratory rate | 25,000 mg/day (262,879 ppm) | |||
| Perinatal death | 100 ppm† (3210 ppm†) | |||
| Miscarriage (hatchability) | 25,000 mg/day (262,879 ppm) | 45 ppm (1155 ppm) | 0.3 ppm (17 ppm) | |
| Decreased fertility | 45 ppm (1155 ppm) | |||
| Decreased milk production | 100 mg/day (1051 ppm) | |||
| Male genitourinary conditions | 100 mg/day (1051 ppm) | |||
| Delayed reproductive development | 100 ppm† (3210 ppm†) | |||
| Thyroid problems | 5 ppm (160 ppm) | |||
| Weight loss (emaciation) | 25,000 mg/day (262,879 ppm) | 125 ppm (3210 ppm) | 200 ppm (6420 ppm) | 0.3 ppm (17 ppm) |
| Delayed growth | 200 ppm (6420 ppm) | |||
| Enzyme induction | 100 ppm† (3210 ppm†) | |||
| Alteration of anesthesia metabolism | 10 ppm (320 ppm) | |||
| Alteration of steroid metabolism | 100 ppm† (3210 ppm†) | |||
| Liver problems | 100 mg/day (1051 ppm) | 10 ppm (320 ppm) | 25 ppm (1452 ppm) | |
| Stomach inflammation | 25 ppm (1452 ppm) | |||
| Skin problems | 100 mg/day (1051 ppm) | 0.3 ppm (17 ppm) | ||
| Diarrhea | 25,000 mg/day (262,879 ppm) | |||
| Excessive salivation | 25,000 mg/day (262,879 ppm) | |||
The level of PBBs fed to various animal models and the health problems that they developed from the exposure. Exposure levels have been converted to the equivalent human exposure levels using accepted conversion equations.
†Effect seen in offspring of mothers exposed to this level of PBBs.
Data taken from [30].
PBB: Polybrominated biphenyl.
Effects of PBBs on animal models standardized by human equivalent dose.
Summary of significant findings in Michigan polybrominated biphenyl registry.